Alnylam Pharmaceuticals this week presented preclinical data from its hemophilia and bleeding disorder program, showing that its subcutaneously administered drug candidate ALN-AT3 could trigger potent, dose-dependent, durable target knockdown in non-human primates.

The company also reported data indicating that its hemoglobinopathy treatment ALN-TMP had disease-modifying effects in an animal model of B-thalassemia.

The data were presented at the 54th American Society of Hematology annual meeting this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

Sep
10
Sponsored by
Qiagen

In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.